Sinovac Biotech Ltd (SVA) - Total Liabilities
Based on the latest financial reports, Sinovac Biotech Ltd (SVA) has total liabilities worth $1.39 Billion USD as of June 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sinovac Biotech Ltd - Total Liabilities Trend (1998–2023)
This chart illustrates how Sinovac Biotech Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore SVA long-term investments to assets to see how much of total assets are deployed in long-term investments.
Sinovac Biotech Ltd Competitors by Total Liabilities
The table below lists competitors of Sinovac Biotech Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tiptree Inc
NASDAQ:TIPT
|
USA | $6.22 Billion |
|
Linewell Software Co Ltd
SHG:603636
|
China | CN¥3.19 Billion |
|
Alpargatas S.A
SA:ALPA3
|
Brazil | R$2.83 Billion |
|
COFCO Joycome Foods Limited
F:0M7
|
Germany | €12.87 Billion |
|
Unizyx Holding Corp
TW:3704
|
Taiwan | NT$11.74 Billion |
|
Isgec Heavy Engineering Limited
NSE:ISGEC
|
India | Rs50.10 Billion |
|
New York Mortgage Trust Inc
NASDAQ:NYMT
|
USA | $9.16 Billion |
|
Nanjing Quanxin Cable Technology Co Ltd
SHE:300447
|
China | CN¥555.18 Million |
Liability Composition Analysis (1998–2023)
This chart breaks down Sinovac Biotech Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Sinovac Biotech Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sinovac Biotech Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sinovac Biotech Ltd (1998–2023)
The table below shows the annual total liabilities of Sinovac Biotech Ltd from 1998 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $1.64 Billion | +16.64% |
| 2022-12-31 | $1.40 Billion | -51.19% |
| 2021-12-31 | $2.87 Billion | +267.66% |
| 2020-12-31 | $781.20 Million | +680.39% |
| 2019-12-31 | $100.10 Million | +28.58% |
| 2018-12-31 | $77.85 Million | -4.70% |
| 2017-12-31 | $81.69 Million | 0.00% |
| 2016-12-31 | $81.69 Million | +22.98% |
| 2015-12-31 | $66.42 Million | -31.39% |
| 2014-12-31 | $96.80 Million | -0.26% |
| 2013-12-31 | $97.05 Million | +22.35% |
| 2012-12-31 | $79.33 Million | +12.35% |
| 2011-12-31 | $70.61 Million | +6.02% |
| 2010-12-31 | $66.60 Million | +9.16% |
| 2009-12-31 | $61.01 Million | +156.32% |
| 2008-12-31 | $23.80 Million | -3.03% |
| 2007-12-31 | $24.55 Million | +56.33% |
| 2006-12-31 | $15.70 Million | +128.94% |
| 2005-12-31 | $6.86 Million | 0.00% |
| 2004-12-31 | $6.86 Million | +71.01% |
| 2003-12-31 | $4.01 Million | +2831.33% |
| 2002-12-31 | $136.81K | -85.63% |
| 2001-12-31 | $952.15K | 0.00% |
| 2000-12-31 | $952.15K | +21058.89% |
| 1998-12-31 | $4.50K | -- |
About Sinovac Biotech Ltd
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza;… Read more